Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

portant biological activity. This dosing regimen is being used in DEFEND. For more information on DEFEND, please see http://www.DefendAgainstDiabetes.com.

Tolerx Collaboration with GlaxoSmithKline

In October 2007, Tolerx and GlaxoSmithKline (GSK) entered into a global alliance to develop and commercialize otelixizumab in numerous indications, including type 1 diabetes. Under the terms of the agreement, Tolerx is responsible for conducting the Phase 3 clinical program for type 1 diabetes in the US and if successful, for submitting the biologics license application (BLA) to the FDA. Tolerx has the option to co-promote otelixizumab in type 1 diabetes in the US with GSK while GSK has exclusive rights to develop and commercialize otelixizumab in all other indications worldwide, including pediatric type 1 diabetes.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development: otelixizumab and a modified version of TRX1, MTRX1011A. MTRX1011A is a humanized anti-CD4 monoclonal antibody being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new monoclonal antibody product candidates that engage the body's immune system and promote and enhance immune responses. These antibodies are being assessed for potential benefit in the treatment of cancer, chronic viral diseases, and as an adjunct to vaccines. For more information, please visit http://www.tolerx.com.

Tolerx Forward-Looking Statements

This press release contains certain statements that are preceded by, followed by, or that include the words "will evaluate," "will," "look forward," "believe," and "has the potential to," or similar expressions or the negation thereof. Such stateme
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PuraMed BioScience®, Inc., (OTC Pink: PMBS), a ... healthcare products, announced it received the initial funding to ... headache relief product, for planned distribution to 1,000 medical ... , Washington State , and ... H Advanced headache relief gel formulation completed, PuraMed BioScience ...
(Date:12/24/2014)... 2014 ResMed (NYSE: RMD ) today ... Chinese medical device manufacturer BMC Medical Co., Ltd. ... masks listed below infringe ResMed,s patents, and entered an order ... the United States : , ... , Willow nasal pillows mask , iVolve full face ...
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2 July, 2007 -- Ablynx today announced ... study of its lead,development programme, ALX-0081, an ... targeting von Willebrand Factor (vWF), which can,reduce ... acute coronary,syndrome. , The Phase I study ...
... own blood can,potentially improve the quality of ... by peripheral vascular disease, according,to a study ... /PRNewswire/ -- Beike,Biotechnology Co., Ltd. (<a target="_blank" ... by Dr. Yang Xiaofeng at its,collaborating hospital ...
Cached Medicine Technology:Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2Beike Biotechnology Study Suggests Adult Stem Cells Show Promise,for Peripheral Vascular Disease 2Beike Biotechnology Study Suggests Adult Stem Cells Show Promise,for Peripheral Vascular Disease 3
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... , , WASHINGTON, Sept. 9 ... health care plan, American Life League challenged the nation,s Catholic bishops ... it clear that they prefer this action to compromising with the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) ...
... ... Education Program are Experts in Child Safety , ... Vancouver, BC (PRWEB) September 9, 2009 -- September sees more than 500,000 ... or after school. So how do parents keep their kids safe when they are in ...
... Workforce Prescriptions ("WRX") announced on Tuesday the launch of the Paradigm ... by a private endowment, developed to honor hospitals that have gone ... without resorting to workforce reductions or dramatic top-down mandates. , ... the paradigm shift in understanding required to see that the number ...
... HILL, N.C., Sept. 9 TSI Healthcare, a national leader in ... recognized in Inc. Magazine,s "Annual Report of the 500|5000 ... successful and innovative businesses in America have been recognized on this ... , , Inc. began publishing this ...
... , , DALLAS, Sept. ... new t-shirt design supporting breast cancer research, ... tee will benefit the Dallas County Affiliate of Susan G. Komen ... black and white - features distinctive Katydid Collection designs, pairing bold ...
... , , LEHI, ... change and full of demands, pressure and stress. This perfect storm ... depressed population - fueling an $80 billion industry of sleep aids, ... XanGo , LLC unveils eleviv(TM), a revolutionary new ...
Cached Medicine News:Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Keeping Kids Safe Through Education 2Health News:WRX Launches National Labor Efficiency Quality Award 2Health News:WRX Launches National Labor Efficiency Quality Award 3Health News:TSI Healthcare Recognized by Inc. Magazine 2Health News:Katydid Collection Creates Tattoo Inspired Komen Shirts to Support Breast Cancer Awareness 2Health News:Katydid Collection Creates Tattoo Inspired Komen Shirts to Support Breast Cancer Awareness 3Health News:Katydid Collection Creates Tattoo Inspired Komen Shirts to Support Breast Cancer Awareness 4Health News:XanGo Introduces a New Dietary Supplement That Restores Youthful Vigor - Naturally 2Health News:XanGo Introduces a New Dietary Supplement That Restores Youthful Vigor - Naturally 3
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
McPherson angled tying forceps made of titanium tying forceps, angled 45 shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 84 mm....
McPherson straight tying forceps made of titanium, straight shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 87 mm....
Titanium hoskin suture tying forceps, 4.75"....
Medicine Products: